Poolbeg Pharma (POLB) investor relations material

Investment highlights

• Experienced leadership team with a strong track record in closing significant transactions.

• High-value clinical-stage programs targeting unmet needs in large, growing markets.

• Financial runway extends to Q2 2028, supporting robust partnering discussions.

• Partnering-focused model with a clear path to strategic transactions.

Pipeline and clinical progress

• Lead asset POLB 001 is a p38 MAPK inhibitor for preventing cancer immunotherapy-induced CRS, with strong preclinical and clinical data.

• POLB 001 has received major patent grants in Europe, Canada, and Australia, with additional territories pending.

• Oral GLP-1R agonist program targets the obesity market, with a proof-of-concept trial planned for H2 2026.

• Multiple near-term clinical milestones, including interim POLB 001 data expected late summer 2026.

Market opportunity and commercial strategy

• CRS prophylaxis market opportunity exceeds $10 billion, driven by the growth of bispecific antibody and CAR-T therapies.

• Independent payer research covering ~75M lives validates willingness to pay for POLB 001 at meaningful price points.

• Effective CRS prevention could enable outpatient administration and broader uptake of cancer immunotherapies.

• Pharma patent cliff and growing number of CRS-inducing therapies create strong partnering interest.